Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours Β· Estimated delivery Aug 22 - Aug 27
The pivotal Phase 2 trial a 48-week study published in The New England Journal of Medicine in 2023 produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly: Average weight loss of around 24% from baseline A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss Continued weight loss right up to the 48-week endpoint, with no plateau in sight For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks
Semaglutide injections have a half-life of about 7 days and are injected once weekly
These treatments offer safe, efficient, and holistic approaches to achieving radiant skin and overall wellness
In addition, this method has also been used in biomarker research for diseases such as diabetes and obesity
Healthcare providers appreciate having additional tools to personalize treatment rather than forcing patients into rigid protocols
